HC Wainwright Issues Positive Forecast for OVID Earnings

Ovid Therapeutics Inc. (NASDAQ:OVID) – Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of Ovid Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.13) per share for the quarter, up from their previous forecast of ($0.16). HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.16) EPS.

OVID has been the subject of several other research reports. Oppenheimer upgraded shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research report on Wednesday, January 29th. Wedbush reaffirmed an “outperform” rating and set a $3.00 target price (down previously from $4.00) on shares of Ovid Therapeutics in a report on Wednesday, March 12th. Finally, BTIG Research cut their price target on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Monday. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $3.03.

Ovid Therapeutics Stock Performance

Shares of NASDAQ:OVID opened at $0.38 on Wednesday. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.18. Ovid Therapeutics has a 1-year low of $0.37 and a 1-year high of $3.45. The stock has a market capitalization of $26.93 million, a P/E ratio of -0.81 and a beta of 0.29. The business has a 50-day moving average price of $0.58 and a two-hundred day moving average price of $0.91.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.19 million. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of OVID. FMR LLC grew its holdings in shares of Ovid Therapeutics by 1,907.4% in the 3rd quarter. FMR LLC now owns 50,225 shares of the company’s stock valued at $59,000 after buying an additional 47,723 shares during the period. Geode Capital Management LLC lifted its holdings in Ovid Therapeutics by 1.1% during the third quarter. Geode Capital Management LLC now owns 1,317,330 shares of the company’s stock worth $1,555,000 after acquiring an additional 14,816 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Ovid Therapeutics by 4,128.7% in the third quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company’s stock valued at $260,000 after acquiring an additional 215,189 shares during the period. Barclays PLC grew its stake in Ovid Therapeutics by 311.2% in the third quarter. Barclays PLC now owns 84,175 shares of the company’s stock valued at $98,000 after acquiring an additional 63,702 shares during the period. Finally, SG Americas Securities LLC increased its holdings in shares of Ovid Therapeutics by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock worth $35,000 after acquiring an additional 17,172 shares in the last quarter. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.